Kit ELISA Troponin I sandwich (TNNI3) (human): quantitative determination of Hu TNNI3 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu TNNI3.
Accession number
P19429
Dose range
125-8000 pg/ml
Sensitivity of the dosage
100 pg/ml
Calibration range
100 pg/ml to 8000 pg/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
Kit ELISA Troponin I sandwich (TNNI3) (human): quantitative determination of Hu TNNI3 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu TNNI3.
Kit ELISA Troponin I sandwich (TNNI3) (human): quantitative determination of Hu TNNI3 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu TNNI3.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
Cardiac troponin I (troponin I, TnI, heart-specific troponin I) is an integral inhibitory protein in the heart muscle that exists as part of a complex with troponin C (TnC) and troponin T (TnT). The TnT subunit of troponin binds to the tropomyosin-t form, a troponin-tropomyosin complex, anchored in place by binding TnI to l的actin, in fine filaments of muscle cells. The structural change resulting from calcium binding to specific sites of the regulatory TnC subunit releases the inhibitory region of TnI from the actin, allowing myosin to be isolated from the molecular motor protein, allowing muscle contraction and therefore movement. Measurements of TnI and TnT levels in the blood are important diagnostic indicators of cardiac muscle damage and can be used to differentiate between breast and myocardial infarction in patients with chest pain. Cardiac troponin I has also been shown to inhibit in vivo and in vitro benzogenesis. The mutations of the Troponine cardiac I gene cause type 7 family hypertrophic cardiomyopathy (CMH7) and family restrictive cardiomyopathy (RCM).